FDA Will Review Multiple Drug Applications in October
Federal regulators have scheduled key rulings on three distinct therapies throughout October 2026.
Updated on Oct. 5, 2026 in Cancer
Live Poll
Will the FDA approve upcoming drug applications for Roche, Viatris, and Opus Genetics this October?
The FDA is set to issue decisions on three medical therapies between October 9 and October 17, 2026. These upcoming rulings follow a month of regulatory activity that included Merck withdrawing its application for Ifinatamab Deruxtecan on September 25.
Why it matters
These PDUFA target deadlines determine whether new treatments will be available to patients, following a rigorous agency review process that can end in approval or a rejection via a Complete Response Letter.
The FDA will review Tecentriq for stage III colon cancer, Enspryng for thyroid eye disease, and MR-141 for presbyopia. The ATOMIC study for Tecentriq enrolled 712 patients, while the SatraGO-2 trial showed 53% of Enspryng patients saw improved eye bulging.
The players
FDA
The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of human drugs.
Merck
Merck is a global pharmaceutical company known for developing innovative medicines and vaccines.
Roche
Roche is a multinational healthcare company that operates in the pharmaceuticals and diagnostics sectors.
Viatris
Viatris is a global healthcare company focused on providing access to medicines for patients across various stages of life.
Opus Genetics
Opus Genetics is a biotechnology company focused on the development of gene therapies for inherited retinal diseases.
The details
The FDA review process entails a thorough examination of clinical trial data to ensure efficacy and safety before a final determination. Merck recently withdrew its application for Ifinatamab Deruxtecan after the agency determined the submitted data was insufficient for accelerated approval.
Timeline
September 25, 2026: Merck withdrew its application for Ifinatamab Deruxtecan.
October 9, 2026: The FDA is expected to rule on Tecentriq for stage III colon cancer.
October 15, 2026: The FDA is expected to rule on Enspryng for thyroid eye disease.
October 17, 2026: The FDA is expected to rule on MR-141 for presbyopia.
The Big Picture
These regulatory milestones are governed by the Prescription Drug User Fee Act (PDUFA) target deadline process. This framework dictates the timeline for FDA reviews, ensuring that the agency completes its evaluation of new drug applications within a set period.
These upcoming decisions could expand treatment options for patients suffering from stage III colon cancer, thyroid eye disease, or presbyopia. Approval would allow these therapies to enter the market, potentially changing standard treatment protocols for these conditions.
The takeaway
These regulatory timelines represent the final hurdle for pharmaceutical companies before a drug can reach the market. Patients and investors monitor these dates closely as they indicate the immediate future of medical access and corporate drug pipelines.
What happens next
The FDA is expected to provide official decisions on Tecentriq on October 9, Enspryng on October 15, and MR-141 on October 17, 2026.
Further reading
For more information on ongoing clinical research, visit the Cancer section.
Source note: This article includes information reported by Asianet News Network Pvt Ltd.
Live Poll
Will the FDA approve upcoming drug applications for Roche, Viatris, and Opus Genetics this October?
